GCM
COLL icon

Gladius Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Gladius Capital Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-830
Closed -$32.1K – 106
2024
Q3 		$32.1K Sell
830
-162
-16% -$5.78K ﹤0.01% 204
2024
Q2 		$31.9K Buy
+992
New +$34.4K ﹤0.01% 227
2024
Q1 		– Sell
-1,370
Closed -$42.2K – 334
2023
Q4 		$42.2K Buy
1,370
+69
+5% +$1.73K 0.01% 199
2023
Q3 		$29.1K Buy
1,301
+234
+22% +$5.34K ﹤0.01% 305
2023
Q2 		$22.9K Sell
1,067
-168
-14% -$3.81K ﹤0.01% 293
2023
Q1 		$29.6K Sell
1,235
-478
-28% -$12.7K ﹤0.01% 287
2022
Q4 		$39.7K Sell
1,713
-358
-17% -$7.22K ﹤0.01% 225
2022
Q3 		$34K Buy
+2,071
New +$36.5K ﹤0.01% 269

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Gladius Capital Management's COLL Position: Q4 2024 in Review

Gladius Capital Management sold out of Collegium Pharmaceutical (COLL) in Q4 2024, closing a stake of 830 shares — an estimated $32.1K sold.

Gladius Capital Management first reported a position in COLL in Q3 2022 and held it in 8 quarters. The position peaked at $42.2K in Q4 2023. 238 funds tracked by Wall St. Rank hold COLL as of Q4 2024.

  • Gladius Capital Management reported no remaining Collegium Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Gladius Capital Management sold 830 Collegium Pharmaceutical shares in Q4 2024, an estimated $32.1K.
  • Gladius Capital Management first reported a position in Collegium Pharmaceutical in Q3 2022 and held it in 8 quarters.
  • Gladius Capital Management's Collegium Pharmaceutical position peaked at $42.2K in Q4 2023.
  • 238 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.